Redeye comments on Optomed’s increased full-year outlook and changes our Q4 2024 sales estimate acco...
Investors House reported Q3 2024 revenue of EUR 2.4m, 10% below our estimate, while net operating in...
Organic sales decline of 7% y-o-y EBIT margin of 7.
STENOCARE A/S (“STENOCARE” or the “Company”) continues to experience tough market conditions in Denm...
Redeye comments on the new ALG.APV-527 phase I data.
Redeye returns with a positive view on the back of Bredband2’s Q3 2024 report which was largely in l...
Redeye leaves a comment on Faron’s recent pipeline update, suggesting that the company may look to e...
SinterCast redovisade en omsättning och bruttomarginal som var lägre än väntat.
Permit appeals fall flat, final decision on 5 December Feasibility study and resource update coming ...
Redeye states that the Q3 report came in below our estimates on both sales and EBITDA.
Redeye shares its initial comments on Kontigo Care’s Q3 2024 results, which showed slight positive d...
Tillväxtmaskinen tuffar på EQL Pharma ökade nettoomsättningen med 43,0 procent i det andra kvartalet...
Redeye provides its comment on Mendus’ Q3 2024 report.
Redeye updates its estimates and valuation following Serstech's Q3 2024 report.
Q3 sales EUR 44m (+5% y-o-y), order intake EUR 36m (-5% y-o-y) Margin improvements but slight declin...
